Amgen Said to Boost Bid for Onyx to $130 a Share

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Three Must-See Charts About the U.S. GDP Report
09:28 - Bloomberg's Matt Boesler examines three charts about wage growth, consumer spending and consumer sentiment. He speaks with Bloomberg's Amanda Lang, Joe Weisenthal and Scarlet Fu on "What'd You Miss?" (Source: Bloomberg)
  • What the European Bank Stress Tests Mean for Markets
  • Taking the Temperature of European Banks
  • Deep Dive: Stock Valuations, Consumer Sentiment